Erasca (ERAS)
(Delayed Data from NSDQ)
$2.54 USD
-0.01 (-0.20%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ERAS 2.54 -0.01(-0.20%)
Will ERAS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ERAS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ERAS
Should You Buy Erasca, Inc. (ERAS) After Golden Cross?
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
ERAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
Other News for ERAS
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
Erasca initiates SEACRAFT-2 Phase 3 trial of naporafenib plus trametinib
Erasca to Present at Upcoming Investor Conferences in June
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
Jaguar Health, Altamira Therapeutics, Erasca among healthcare movers